Human kcnq5 potassium channel, methods and compositions thereof
CA 2410489 A1 · Owner: Trojnacki, Joanne T. · Inventors: Dworetzky, Steven I.; Ramanathan, Chandra S.; Gribkoff, Valentin K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An isolated polynucleotide encoding a novel potassium channel polypeptide KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover the hKCNQ5 polypeptide , can be used to assay for KCNQ5 potassium channel modulators which can be , utilized in the treatment of neurological neurophysiological, neuropsychological and neuroaffective diseases conditions and disorders, including, but not limited …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 24, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 24, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 24, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.